Document Detail


Effect of a low molecular weight, high-purity β-glucan on in vitro digestion and glycemic response.
MedLine Citation:
PMID:  21561391     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
β-Glucans are believed to lower postprandial glycemia due to their ability to increase viscosity and slow down gastric emptying. The effect of high-purity barley β-glucan (Glucagel™) was tested on in vitro starch digestibility and glycemic response of chapattis. In a randomized controlled crossover trial, 10 healthy human subjects consumed chapattis containing 0, 4 and 8% β-glucan on different occasions. Capillary blood samples were collected before and at 0, 15, 30, 45, 60, 90 and 120 min after consuming the chapattis. There was no significant difference either in the amount of glucose released after in vitro digestion or in the glycemic response to chapattis with 0, 4 and 8% β-glucan (P>0.05). It may be concluded that low molecular weight barley β-glucan, although of 75% purity, was not effective in lowering glycemic response possibly due to its inability to influence starch digestion and particle breakdown during in vitro digestion.
Authors:
Pariyarath Sangeetha Thondre; Christiani Jeya Kumar Henry
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-5-12
Journal Detail:
Title:  International journal of food sciences and nutrition     Volume:  -     ISSN:  1465-3478     ISO Abbreviation:  -     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-5-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9432922     Medline TA:  Int J Food Sci Nutr     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Functional Food Centre, School of Life Sciences, Oxford Brookes University Oxford , UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Association of APE1 and hOGG1 polymorphisms with colorectal cancer risk in a Turkish population.
Next Document:  Pregabalin or placebo used adjunctively with levetiracetam in refractory partial-onset epilepsy: a p...